Deal, C,
Steelman, J,
Vlachopapadopoulou, E,
Stawerska, R,
Silverman, LA;,
Phillip, M,
Kim, HS,
Ko, CW,
Malievskiy, O,
Cara, JF,
Roland, CL,
Taylor, CT,
Valluri, SR,
Wajnrajch, MP,
Pastrak, A,
Miller, BS (2022) .
Methods: In this 12-month,
open-label, randomized, active-controlled, parallel-group, phase 3 study
Maniatis, AK;,
Casella, SJ;,
Nadgir, UM;,
Hofman, PL;,
Saenger, P;,
Chertock, ED;,
Aghajanova, EM;,
Korpal-Szczyrska, M;,
Vlachopapadopoulou, E;,
Malievskiy, O;,
Chaychenko, T;,
Cappa, M;,
Song, WJ;,
Mao, M;,
Mygind, PH;,
Smith, AR;,
Chessler, S;,
Komirenko, AS;,
Beckert, M;,
Aimee, D Shu,
Paul, S Thornton (2022) Purpose: The objectives of the ongoing, Phase 3,
open-label extension trial enliGHten are to assess
Kovalev, A,
Sufianov, R,
Prevedello, D,
Borba, L,
Mastronardi, L,
Ilyasova, T,
Daniel, RT,
Messerer, M,
Rassi, M,
Zhang, G (2022) an approach remains relevant and
open not only between the “
open” and “endoscopic transnasal” access groups